Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WT1 mRNA-loaded dendritic cell vaccine + cisplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Antwerp University Hospital
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Intravenous
01
Overview
This investigational chemo-immunotherapy regimen is being developed by the University Hospital, Antwerp (UZA) for the first-line treatment of malignant pleural mesothelioma. The therapy combines standard-of-care chemotherapy (cisplatin and pemetrexed) with an autologous dendritic cell vaccine. The vaccine component consists of the patient's own dendritic cells that have been electroporated with messenger RNA (mRNA) encoding the Wilms' Tumor 1 (WT1) antigen, a protein highly expressed in mesothelioma cells. This approach aims to leverage the debulking and potentially immunogenic effects of chemotherapy while simultaneously priming the immune system to recognize and attack WT1-expressing tumor cells. The dendritic cell product is generated at the Center for Cell Therapy and Regenerative Medicine (CCRG) at Antwerp University Hospital and is currently being evaluated in the Phase I/II MESODEC trial.
- Other names
- WT1-targeted DC vaccination + chemotherapyautologous WT1 mRNA-loaded DC vaccinationWT1 mRNA-loaded dendritic cell vaccineWT-1 mRNA-loaded dendritic cell vaccineWT 1 mRNA-loaded dendritic cell vaccine
02
Targets
TS (Thymidylate synthase)WT1 (Wilms tumor protein)DNA
Beyond the preview
Go deeper on WT1 mRNA-loaded dendritic cell vaccine + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WT1 mRNA-loaded dendritic cell vaccine + cisplatin + pemetrexed.